Cargando…

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis

Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iznardo, Helena, Roé, Esther, Serra-Baldrich, Esther, Puig, Lluís
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960033/ https://www.ncbi.nlm.nih.gov/pubmed/36839707 http://dx.doi.org/10.3390/pharmaceutics15020385

Ejemplares similares

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
por: Li, Ling, et al.
Publicado: (2023)

The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
por: Napolitano, Maddalena, et al.
Publicado: (2021)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Efficacy of abrocitinib for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Zhang, Daojun, et al.
Publicado: (2021)

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial
por: Gooderham, Melinda J., et al.
Publicado: (2019)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Gao, Qin, et al.
Publicado: (2023)

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
por: Zhao, Jiahui, et al.
Publicado: (2022)

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Fadlalmola, Hammad Ali, et al.
Publicado: (2021)

JAK1 inhibitor abrocitinib for the treatment of steroid-induced rosacea: case series
por: Xu, Bingyang, et al.
Publicado: (2023)

Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report
por: Ren, Mingyang, et al.
Publicado: (2023)

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023)

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
por: Iznardo, Helena, et al.
Publicado: (2021)

Dual inhibition of IL-17A and IL-17F in psoriatic disease
por: Iznardo, Helena, et al.
Publicado: (2021)

Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
por: Soto, Elena, et al.
Publicado: (2020)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
por: Simpson, Eric L., et al.
Publicado: (2021)

A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
por: Teng, Yan, et al.
Publicado: (2023)

JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
por: Szalus, Krzysztof, et al.
Publicado: (2020)

Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
por: Kamata, Masahiro, et al.
Publicado: (2023)

Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Wang, Junqiao, et al.
Publicado: (2022)

A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors
por: Tampa, Mircea, et al.
Publicado: (2023)

Management of atopic dermatitis: safety and efficacy of phototherapy
por: Patrizi, Annalisa, et al.
Publicado: (2015)

New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration
por: Qi, Hong-jiao, et al.
Publicado: (2021)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
por: Alexis, Andrew, et al.
Publicado: (2022)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

Successful Treatment of Atopic Dermatitis with a Predominant Nipple Involvement by Abrocitinib During COVID-19 Pandemic: A Case Report
por: Teng, Yan, et al.
Publicado: (2023)

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives
por: Niculet, Elena, et al.
Publicado: (2022)

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey
por: Sastre, Joaquín, et al.
Publicado: (2020)

High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents
por: Ständer, S., et al.
Publicado: (2022)

Dupilumab therapy following JAK inhibitor withdrawal in moderate–severe atopic dermatitis
por: Kiely, Lisa, et al.
Publicado: (2022)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s6chso3midgtc5fgn056h9u6r1